Because certain types of immunodeficiency may be induced with anti-CCR7 therapy, additional research is required to develop alternative strategies, such as targeting CCR7 exclusively in cancer cells or inhibiting CCR7-associated signal transduction pathways. The gene discussed is CCR7; the disease is cancer.